Ask about this productRelated genes to: FMNL2 Blocking Peptide
- Gene:
- FMNL2 NIH gene
- Name:
- formin like 2
- Previous symbol:
- FHOD2
- Synonyms:
- KIAA1902
- Chromosome:
- 2q23.3
- Locus Type:
- gene with protein product
- Date approved:
- 2002-02-19
- Date modifiied:
- 2015-11-12
Related products to: FMNL2 Blocking Peptide
Related articles to: FMNL2 Blocking Peptide
- Primary open-angle glaucoma (POAG) is a common eye disorder that can lead to irreversible vision loss. Although genome-wide association studies (GWAS) have identified several genetic loci associated with POAG risk, the specific causative genes and mechanisms remain unclear. - Source: PubMed
Pan ZhengLiu KeJiang BingDong Chuning - The extended therapeutic duration required for pulmonary tuberculosis (PTB) treatment and current limitations in bacteriological gold standards for cure assessment may lead to premature discharge of incompletely cured patients, thereby elevating risks of disease transmission and drug resistance emergence. Host-directed biomarker research holds promise as a valuable adjunct to existing PTB cure evaluation standards, potentially enhancing diagnostic precision and therapeutic monitoring. Transcriptomic biomarkers represent a promising research direction and constitute the focal point of this study. - Source: PubMed
Publication date: 2026/03/21
Li Zhi-BinDong XiaotaoChen Jia-XiLiu JunJiang Ting-TingJia Meng-QiYu YiLv ShuangyuLi Ji-Cheng - While parental astigmatism is a known risk factor for childhood astigmatism, the molecular genetic basis remains elusive. Previous genetic studies, largely confined to adult corneal and refractive astigmatism (CA and RA), did not address internal astigmatism (IA) and astigmatism vector components. We aimed to determine whether genes previously identified to have associations with corneal curvature (CR), CA, and RA in adults similarly occur for CR, CA, RA, IA, and astigmatism vector components (J0 and J45) in children. - Source: PubMed
Publication date: 2025/12/01
Zaabaar EbenezerShing EricaWang Yu YaoKam Ka WaiTam Pancy O SYoung Alvin LTham Clement CPang Chi PuiYam Jason CChen Li Jia - Obesity is a major health challenge and fat accumulation in visceral depots is more strongly associated with metabolic comorbidities than deposition in subcutaneous depots. Epitranscriptomic regulation of gene expression by N-methyladenosine (mA) influences various aspects of RNA metabolism, however the mA methylome in human adipose tissue and its relationship with fat distribution has not yet been investigated in detail. - Source: PubMed
Publication date: 2025/11/12
Rønningen TorunnZeng YongDahl Mai BrittWang JunbaiVisnovska TinaTannæs Tone Møllerla Cour Poulsen LarsCayir AkinSvensson Stina Ingrid AliceSvanevik MariusHertel Jens KristofferHjelmesæth JøranKristinsson Jon AMala TomBlüher MatthiasHe Housheng HansenValderhaug Tone GretlandBöttcher Yvonne - Cytoskeleton-associated protein 4 (CKAP4) has emerged as a critical player in gastrointestinal (GI) cancer progression, diagnosis, and therapy. This comprehensive review synthesizes current knowledge on CKAP4's multifaceted roles across GI malignancies, providing novel insights into its mechanisms of action and clinical potential. Its interaction with DKK1 and subsequent activation of the PI3K/AKT pathway underscores its role in promoting tumor growth. This review also highlights novel insights into CKAP4's mechanisms of action beyond the well-established DKK1-CKAP4 axis, including its interaction with integrin β1 and involvement in angiogenesis through the FMNL2/EGFL6/CKAP4/ERK pathway. CKAP4's impact on tumor microenvironment and immune evasion is elucidated, offering a new perspective on its contribution to cancer progression. In addition, CKAP4 arises as a promising serum biomarker for early detection and prognosis across multiple GI cancers, emphasizing its potential superiority over traditional markers. The therapeutic potential of targeting CKAP4 is extensively explored, including novel approaches like anti-CKAP4 antibodies and aptamers, and their synergistic effects with existing treatments. By integrating findings from esophageal, gastric, pancreatic, and colorectal cancers, this review provides a unique, comprehensive overview of CKAP4 in GI oncology, underscoring CKAP4's potential to revolutionize GI cancer diagnosis and treatment and paving the way for future translational research. - Source: PubMed
Publication date: 2025/10/07
Despotidis MarkosLyros OrestisDriva Tatiana SSakarellos PanagiotisThieme RenéMamilos AndreasSakellariou StratigoulaSchizas Dimitrios